LinkMed

The LinkMed portfolio consists of a number of life science companies, several of which are nearing the commercialization phase, while others are already selling their products or services. Between them, these companies account for more than 50 different projects in a wide range of therapeutic areas – from HIV and cancer to eye disease and allergies.

COMPANIES IN SEVERAL SECTORS
LinkMed has created a portfolio of twelve companies, four in drug development and biotechnology and eight in diagnostics and medical technology

MANY COMPANIES, LOWER RISKS
By investing in several companies, we spread risks and reduce our exposure to the development in individual projects. Our goal is to continually develop and manage between 15 and 20 portfolio companies. Therefore, we plan to invest in several new companies in the coming years.

For safer infusion and injection treatments

Operations: Pharmacolog develops systems to control the content and concentration of liquid pharmaceutical drugs, primarily chemotherapy for the treatment of cancer.

Sektor: Diagnostics and medical technology

Therapeutic area: Chemotherapy for cancer treatment, intensive care, anesthesia etc.

CEO: Kjell Westerlund

Chairman: Lars Martin

Venture manager: Lars Martin

Ownership stake: 41,7%

Address: Pharmacolog i uppsala AB
Vallvägen 4B
Se-7555 51 Uppsala
Sweden

www.pharmacolog.se

Back